Välkommen till Via TT - det enkla pressverktyget

Darmstadt, November 25, 2022 – The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany. "Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations." This means laboratories can continue to reliably con

Stiftelsen Curt Bergfors är stolt över att kunna tilldela 2022 års Food Planet Prize och den tillhörande prissumman om två miljoner dollar vardera, till ColdHubs för dess arbete med att radikalt minska svinnet av mat i producentledet i Nigeria, Afrikas folkrikaste land, och till Global Mangrove Alliance, för dess kooperativa modell för bevarandet av mangroveskogar.